Plus, news from Skye Bioscience, Mediar Therapeutics and Servier.
A first look at Excision’s HIV gene editing clinical trial: The company said Wednesday that three patients have been dosed in the Phase I/II study so far, with mild grade 1 side effects related to the therapy, known as EBT-101. Two…
Click here to view original post
